The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity

The conditionally replicating oncolytic adenovirus Delta24-RGD (Ad) is currently under investigation in clinical trials for glioblastoma, including in combination with temozolomide (TMZ), the standard chemotherapy for this tumor. Previously, we showed that the efficacy of Delta24-RGD in a murine mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleijn, Anne, van den Bossche, Wouter, Haefner, Erik S., Belcaid, Zineb, Burghoorn-Maas, Chantal, Kloezeman, Jenneke J., Pas, Suzan D., Leenstra, Sieger, Debets, Reno, de Vrij, Jeroen, Dirven, Clemens M.F., Lamfers, Martine L.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415315/
https://www.ncbi.nlm.nih.gov/pubmed/28480325
http://dx.doi.org/10.1016/j.omto.2017.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415315/
https://www.ncbi.nlm.nih.gov/pubmed/28480325
http://dx.doi.org/10.1016/j.omto.2017.02.002

Ejemplares similares